Pages that link to "Q36507830"

The following pages link to Determinants of chemosensitivity in gastric cancer (Q36507830):

Displaying 23 items.

• Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. (Q27863379) (← links)
• Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis (Q33321790) (← links)
• ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel (Q33327609) (← links)
• A metabonomic approach to chemosensitivity prediction of cisplatin plus 5‐fluorouracil in a human xenograft model of gastric cancer (Q33829758) (← links)
• Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin (Q34005444) (← links)
• BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer (Q34621524) (← links)
• The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis (Q35175390) (← links)
• Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer (Q36224775) (← links)
• Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges (Q36974685) (← links)
• Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival (Q37123491) (← links)
• Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution's experience (Q37265612) (← links)
• Docetaxel: its role in current and future treatments for advanced gastric cancer (Q37627676) (← links)
• ERCC1: impact in multimodality treatment of upper gastrointestinal cancer (Q37818224) (← links)
• Metabolomic studies of human gastric cancer: review (Q38227841) (← links)
• Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells (Q38452910) (← links)
• GTSP1 expression in non-smoker and non-drinker patients with squamous cell carcinoma of the head and neck. (Q40089912) (← links)
• A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. (Q40690113) (← links)
• A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites (Q41686298) (← links)
• ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer (Q43541762) (← links)
• Polymorphism in glutathione S-transferases: susceptibility and treatment outcome for head and neck cancer (Q51852328) (← links)
• Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy (Q82748783) (← links)
• Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression (Q92766578) (← links)
• A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer (Q100941614) (← links)